# Risperidone for the Treatment of Huntington's Disease Involuntary Movements

> **NCT04201834** · PHASE2 · COMPLETED · sponsor: **University of Rochester** · enrollment: 6 (actual)

## Conditions studied

- Huntington Disease
- Chorea

## Interventions

- **DRUG:** Risperidone
- **DEVICE:** BioStamp nPoint device

## Key facts

- **NCT ID:** NCT04201834
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-13
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04201834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04201834, "Risperidone for the Treatment of Huntington's Disease Involuntary Movements". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04201834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*